Is Lorlatinib a drug targeting alk gene mutation?

Lorlatinib (Lorlatinib) is a targeted drug targeting ALK (tyrosine kinase) gene mutations. ALKGene mutations are a specific molecular abnormality in non-small cell lung cancer (NSCLC) that can lead to uncontrolled growth and spread of tumor cells. Lorlatinib was developed to specifically inhibit the effects of this gene mutation, thereby preventing the growth of cancer cells and providing new treatment options for patients.

Lorlatinib is a tyrosine kinase inhibitor that works by inhibiting the activity ofALK protein. The abnormal activity of ALK protein is closely related to the development and progression of NSCLC. Lorlatinib can interfere with the ALK signaling pathway, thereby slowing or stopping the growth and spread of tumor cells and helping to control lung cancer.

Lorlatinib is mainly used to treat ALKpositiveNSCLC patients, especially those with advanced or metastatic disease. It has been approved for use in this specific patient population as a first- or later-line treatment option.

Although lorlatinib is a targeted drug, it may still be associated with some side effects, including fatigue, cough, shortness of breath, nausea, vomiting, headache, high blood pressure, etc. Patients need to monitor regularly while taking lorlatinib and share any discomfort or concerns with their doctor.

Lorlatinib has been launched in China and is included in medical insurance. Patients can purchase it domestically, but the price is relatively high, about 10,000 to 20,000 yuan. For details, please consult the local hospital pharmacy. There are original drugs and cheaper generic drugs abroad. The cheaper ones are the original drugs from Turkey, which cost more than 1,000 yuan, and the original drugs from Hong Kong, China, which cost about 30,000 yuan. Generic drugs are mainly generic drugs from Laos and Bangladesh. The price is about several thousand yuan, and the ingredients of the original drugs and generic drugs are basically the same.